
583	141	

5. A pharmaceutical composition, comprising:

a compound of claim 1, and

a pharmaceutically acceptable adjuvant, carrier, or vehicle.

6. A pharmaceutical composition as claimed in claim 5 for treating a TLR7/8-mediated disorder in a patient in need thereof, comprising:

administering to said patient a compound of claim 1 or a pharmaceutically acceptable salt thereof.

7. The pharmaceutical composition of claim 6, wherein the disorder is selected from the group consisting of Rheumatoid Arthritis, Psoriatic arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Lupus nephritis, Ankylosing Spondylitis, Osteoporosis, Systemic sclerosis, Multiple Sclerosis, Psoriasis, Type I diabetes, Type II diabetes, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Hyperimmunoglobulinemia D, periodic fever syndrome, Cryopyrin-associated periodic syndromes, Schnitzler's syndrome, Systemic Juvenile idiopathic arthritis, Adult's onset Still's disease, Gout, Pseudogout, SAPHO syndrome, Castleman's disease, Sepsis, Stroke, Atherosclerosis, Celiac disease, DIRA (Deficiency of IL-1 Receptor Antagonist), Alzheimer's disease, and Parkinson's disease.